Alexandria, VA, United States

United States Patent and Trademark

www.uspto.gov
Alexandria, VA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 9, 2017
Site: www.prweb.com

The United States Patent and Trademark Office has issued U.S. Patent No. 9,618,476 to Nanomedical Diagnostics, a biotech company pioneering label-free graphene biosensors for use in drug discovery. The patent covers any holistic graphene biosensor system that detects biomolecular interactions and is a foundational patent behind the company’s AGILE R100 platform. “This patent showcases our company commitment to bringing cutting-edge nanotechnology to the life science world,” says Nanomedical Diagnostics founder and CTO, Dr. Brett Goldsmith, also the inventor named on the patent. “Graphene biosensors solve many problems encountered with current sensing tools and enable capabilities that aren’t possible with existing techniques. We are committed to developing graphene biosensors into sensitive measurement tools that help biomedical researchers make confident decisions earlier. The issuance of this patent demonstrates that.” The patent issue highlights the achievement of the Nanomedical Diagnostics technology team in developing a novel approach for label-free detection of biomolecular interactions. The ability to leverage graphene biosensors in a user-friendly, complete system enables sensitivity, small sample sizes, portability, and ease of use that open new applications in the fields of drug discovery, disease diagnostics, health monitoring, and biomanufacturing. AGILE R100 is available for commercial sale, for research use only.


News Article | May 9, 2017
Site: globenewswire.com

BURBANK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG) announced today that it filed an Amendment to the Annual Report of Form 10-K for the year ended December 31, 2016 to correct certain disclosures concerning the Company’s proprietary technology designated “Apparatus and Method for Three Dimensional Real-Time Imaging Systems” (the “Technology”), as set forth on pages 3 and 45 of the Form 10-K. The Form 10-K erroneously states that the active patent currently covering Imaging3’s Technology is U.S. Patent No. 6,754,297. In fact, on August 28, 2002 Dean Janes (“Janes”), the Company’s founder, filed the original patent application for the Technology; and, on June 22, 2004, the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 6,754,297 covering the Technology to the Company as assignee. After making substantial improvements to the design and utility of the Technology, Janes, on June 21, 2004, filed a second patent application covering the Technology that incorporated the aforementioned improvements. On January 8, 2008, the USPTO issued patent No. 7,317,819 covering the improved Technology to the Company as assignee. On June 22, 2008, subsequent to the issuance of U.S. Patent No. 7,317,819, the Company intentionally allowed U. S. Patent No. 6,754,297 to expire for non-payment of required maintenance fees. Assuming continued payment of maintenance fees, U.S. Patent No. 7,317,819 expires no sooner than June 21, 2024; due to provisions in Title II of the Drug Price Competition and Patent Term Restoration Act, the patent term could be extended beyond this date. President Dane Medley stated: “We sincerely apologize for the confusion concerning the patent numbers.  The takeaway here is that our unique ability to provide 3-D imaging, virtually in real time, is covered by an active patent.” Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called SmartScan™, that will produce 3D x-ray images, virtually in real time. The SmartScan technology will allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. In addition, Imaging3’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company believes will allow scans to be used in more pediatric applications than are currently prescribed. The technology also allows for greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is planning to submit a 510K application to the FDA during 2017 in order to gain approval to commercialize the SmartScan technology. Visit the company’s website at http://www.imaging3.com for detailed information about the Company’s technology. Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market success to sustain a profitable business.  In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q.  Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


News Article | May 9, 2017
Site: www.businesswire.com

SEATTLE--(BUSINESS WIRE)--Visualant, Incorporated (OTCQB: VSUL) – an emerging leader in next-generation optical sensor technology – announced today that it has received its 11th U.S. patent. The invention relates to the use of the company’s disruptive ChromaID™ technology for identifying and analyzing biological tissue, and has many potential applications in healthcare, food safety, cosmetics and other medical, industrial and consumer markets. ChromaID is a platform technology that employs frequency-specific structured light to detect unique spectral patterns that occur naturally in virtually any type of substance or object. Unlike legacy optical sensor technology such as mass spectrometry, ChromaID sensors can provide highly accurate information at a significantly lower cost and in a small and flexible form factor. ChromaID sensors can be easily integrated into a variety of both hand-held and stationary systems used for inspection, analysis and authentication. ChromaID’s affordability, unique functionality and compact size make it an attractive offering for both the consumer-facing and enterprise Internet of Things (IoT) ecosystems. The Visualant ChromaID technology, as applied to the evaluation of biological tissue, will allow for a wide variety of real-world applications involving identification and diagnostics, including medical diagnostics, food safety and quality control and cosmetic analysis. Examples may include real-time detection of bacterial contamination, identification of certain skin diseases, contaminants on meat, fish and poultry, among many other applications. The company’s recently announced Joint Development Agreement with Biomedx, which is focused on the properties of human skin, falls squarely within the scope of the newly issued patent. That agreement provides for the use of ChromaID to analyze collagen and elastin as an aid in plastic reconstructive and cosmetic surgery. Visualant Founder and CEO Ron Erickson stated, “We believe this new patent will prove to be one of our most significant to date as it provides a foundation for the pursuit of a number of consumer, medical and industrial diagnostic and authentication applications. We continue to attract enthusiastic interest as we develop and pursue partnering opportunities in each of these large, global markets. We believe that the availability of strong patent protection helps to give our partners confidence that the products that they bring to market based on ChromaID technology can enjoy a significant and lasting competitive advantage.” The patent, issued by the United States Patent and Trademark Office as US Patent No. 9,625,371 B2, is entitled “Method, Apparatus, and Article to Facilitate Evaluation of Substances Using Electromagnetic Energy.” This newly issued patent continues the expansion of the Visualant intellectual property portfolio. The company continues to have a significant number of pending patents and aggressively works to expand the reach of the ChromaID technology. Visualant™ is a public company whose shares trade under the stock symbol “VSUL.” The Visualant Spectral Pattern Matching™ (SPM) technology directs structured light onto a substance or material, through a liquid or gas, or off a surface, to capture a unique ChromaID™. A ChromaID can be used to identify, detect, or diagnose markers invisible to the human eye. ChromaID scanner modules can be integrated into a variety of mobile or fixed-mount form factors. The patented, award-winning technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab-based tests. For more information on Visualant, visit the company’s website at www.visualant.net.


News Article | May 9, 2017
Site: globenewswire.com

BURBANK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG) announced today that it filed an Amendment to the Annual Report of Form 10-K for the year ended December 31, 2016 to correct certain disclosures concerning the Company’s proprietary technology designated “Apparatus and Method for Three Dimensional Real-Time Imaging Systems” (the “Technology”), as set forth on pages 3 and 45 of the Form 10-K. The Form 10-K erroneously states that the active patent currently covering Imaging3’s Technology is U.S. Patent No. 6,754,297. In fact, on August 28, 2002 Dean Janes (“Janes”), the Company’s founder, filed the original patent application for the Technology; and, on June 22, 2004, the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 6,754,297 covering the Technology to the Company as assignee. After making substantial improvements to the design and utility of the Technology, Janes, on June 21, 2004, filed a second patent application covering the Technology that incorporated the aforementioned improvements. On January 8, 2008, the USPTO issued patent No. 7,317,819 covering the improved Technology to the Company as assignee. On June 22, 2008, subsequent to the issuance of U.S. Patent No. 7,317,819, the Company intentionally allowed U. S. Patent No. 6,754,297 to expire for non-payment of required maintenance fees. Assuming continued payment of maintenance fees, U.S. Patent No. 7,317,819 expires no sooner than June 21, 2024; due to provisions in Title II of the Drug Price Competition and Patent Term Restoration Act, the patent term could be extended beyond this date. President Dane Medley stated: “We sincerely apologize for the confusion concerning the patent numbers.  The takeaway here is that our unique ability to provide 3-D imaging, virtually in real time, is covered by an active patent.” Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called SmartScan™, that will produce 3D x-ray images, virtually in real time. The SmartScan technology will allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. In addition, Imaging3’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company believes will allow scans to be used in more pediatric applications than are currently prescribed. The technology also allows for greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is planning to submit a 510K application to the FDA during 2017 in order to gain approval to commercialize the SmartScan technology. Visit the company’s website at http://www.imaging3.com for detailed information about the Company’s technology. Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market success to sustain a profitable business.  In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q.  Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


News Article | May 10, 2017
Site: www.marketwired.com

NEW YORK, NY--(Marketwired - May 10, 2017) - Network-1 Technologies, Inc. ( : NTIP) announced today that its wholly-owned subsidiary, Mirror Worlds Technologies, LLC ("MWT"), has initiated patent litigation against Facebook, Inc. ("Facebook") in the United States District Court for the Southern District of New York for infringement of U.S. Patent No. 6,006,227, U.S. Patent No. 7,865,538, and U.S. Patent No. 8,255,439 (collectively, the "Patents in Suit"). The lawsuit alleges that the Patents in Suit are infringed by the core technologies that enable both Facebook's Newsfeed, which according to Time Magazine is the "epicenter of its success," and Facebook's Timeline features. The lawsuit further alleges that Facebook's unauthorized use of the stream-based solutions of the Patents in Suit has helped Facebook become the most popular social networking site in the world with more than 1.94 billion monthly active users as of March 2017. The Patents in Suit are among the patents acquired by Network-1, through MWT, from Mirror Worlds, LLC on May 21, 2013 and relate to computer systems using stream-based solutions. The inventions described in the Patents in Suit resulted from the work done by Yale University computer scientist, Professor David Gelernter, his then graduate student, Dr. Eric Freeman, and their co-inventors in the mid-1990s. As reported in The Economist, "Dr. Gelernter foresaw how computers would be woven into the fabric of everyday life. In his book 'Mirror Worlds,' published in 1991, he accurately described websites, blogging, virtual reality, streaming video, tablet computers, e-books, search engines and internet telephony. More importantly, he anticipated the consequences all this would have on the nature of social interaction, describing distributed online communities that work just as Facebook and Twitter do today."1 Professor Gelernter and Dr. Freeman, and their co-inventors' stream-based solution was envisioned as an electronic diary of a user's entire life. It would contain documents, photos, messages or web pages the user interacted with -- all in a single, searchable stream, and held safely online. Individual items could be shared with other people. The stream could also blend with millions of other streams, with a simple way to control the flow of information so as not to overwhelm the user. It would represent the user's personal life and public life and could function as a confidential electronic diary. Since Network-1's acquisition of the Mirror Worlds patent portfolio in May 2013, Network-1 has achieved licensing revenue and other revenue of an aggregate of $47,150,000 which includes, among other things, license agreements with Apple and Microsoft. The validity of the '227 Patent has been reaffirmed by the U.S. Patent and Trademark Office in reexamination proceedings initiated by Apple resulting in two re-examination certificates and additional allowed claims. In addition, the Patent Trial and Appeal Board of the U.S. Patent Office denied institution of a Covered Business Method Review (CBM) filed by Apple challenging the validity of the '227 Patent concluding that Apple's challenge was not likely to succeed. Network-1 Technologies, Inc. is engaged in the development, licensing and protection of its intellectual property and proprietary technologies. Network-1 works with inventors and patent owners to assist in the development and monetization of their patented technologies. Network-1 currently owns thirty-three (33) patents covering various telecommunications and data networking technologies as well as technologies relating to document stream operating systems and the identification of media content. Network-1's current strategy includes continuing to pursue licensing opportunities for its Remote Power Patent and its efforts to monetize two patent portfolios (the Cox and Mirror Worlds patent portfolios) acquired by Network-1 in 2013. Network-1's acquisition strategy is to focus on acquiring high quality patents which management believes have the potential to generate significant licensing opportunities as Network-1 has achieved with respect to its Remote Power Patent and Mirror Worlds Patent Portfolio. Network-1's Remote Power Patent has generated licensing revenue in excess of $105,000,000 from May 2007 through December 31, 2016. As a result of the acquisition of its Mirror Worlds Patent Portfolio in May 2013, Network-1 achieved licensing and other revenue of $47,150,000 through December 31, 2016 with respect to its Mirror Worlds Patent Portfolio. This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements address future events and conditions concerning Network-1's business plans. Such statements are subject to a number of risk factors and uncertainties as disclosed in the Network-1's Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission, including, among others, the continued validity of Network-1's Remote Power Patent, the ability of Network-1 to successfully execute its strategy to acquire high quality patents with significant licensing opportunities, Network-1's ability to achieve revenue and profits from its Cox Patent Portfolio and additional revenue and profit from its Mirror Worlds Patent Portfolio as well as intellectual property it may acquire in the future, the ability of Network-1 to enter into additional license agreements, the ability of Network-1 to continue to receive material royalties from its existing license agreements for its Remote Power Patent, the uncertainty of patent litigation and proceedings at the United States Patent and Trademark Office, the difficulty in Network-1 verifying royalty amounts owed to it by its licensees, Network-1's ability to enter into strategic relationships with third parties to license or otherwise monetize their intellectual property, the continued viability of the PoE market, the risk in the future of Network-1 being classified as a Personal Holding Company, future economic conditions and technology changes and legislative, regulatory and competitive developments. Except as otherwise required to be disclosed in periodic reports, Network-1 expressly disclaims any future obligation or undertaking to update or revise any forward-looking statement contained herein 1 Seer of the mirror world, The Economist, Technology Quarterly, Vol. Q4 2011 (Dec. 3, 2011)


News Article | May 9, 2017
Site: globenewswire.com

VANCOUVER, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BUR) (“Burcon”) is pleased to announce today that it has been granted a U.S. patent, covering technology for the production of its Peazazz® pea protein:  U.S. patent no. 9,635,875, was granted on May 2, 2017.  This patent is the first to be granted for Burcon’s pea technology by the United States Patent and Trademark Office and confirms that the Company’s approach is unique, distinct and defensible.  Burcon anticipates further positive progress, with its patent filings, in due course.  Burcon also announces today that it has been granted two more U.S. patents covering technologies for the production of CLARISOY™, and it has also received two notices of allowance from the United States Patent and Trademark Office for two more patents for the production of CLARISOY™ soy protein.  A notice of allowance from the United States Patent and Trademark Office is a written notification that a patent application has cleared internal review, is pending issuance and will grant in the near future.  CLARISOY™ soy protein patents: U.S. patent no. 9,629,381 was granted April 25, 2017; and U.S. patent no. 9,603,377 was granted on March 28, 2017; and U.S. patent application 15/094386 was allowed on March 14, 2017, and U.S. patent application 14/117384 was allowed on March 29, 2017. The five U.S. patent grants and allowances, as announced above, bring the company’s patent portfolio to over 215 issued patents in various countries, including 65 in the U.S., as well as over 350 active patent applications, including 47 additional U.S. patent applications. Also, during the first part of 2017, Burcon continued its efforts toward commercializing its other unique plant protein extraction technologies. Burcon has focused in particular on working with a select group of potential partners in the commercialization process for our Peazazz® pea protein. The team at the Winnipeg Technical Centre continues to support these ongoing discussions with: due diligence visits; applications work; and sample production. The potential partners’ activities have included undertaking applications work, detailed market analyses and the investigation of production logistics. "The interest in, and need for, alternative plant protein ingredients continue to be a major trend within the food, beverage and nutritional products industries," said Johann Tergesen, Burcon’s president and chief operating officer, adding, “We are thrilled to see Burcon’s novel plant proteins progressing toward full commercialization and are confident of our ability to profit from this major trend.”  About Burcon NutraScience Corporation Burcon NutraScience is a leader in developing functionally and nutritionally valuable plant-based proteins. The company has developed a portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon’s CLARISOY™ soy protein offers clarity and high-quality protein nutrition for low pH beverage systems and excellent solubility and exceptionally clean flavor at any pH; Peazazz® is a uniquely soluble and clean-tasting pea protein; and Puratein®, Supertein® and Nutratein® are canola protein isolates with unique functional and nutritional attributes. For more information about the company, visit www.burcon.ca. The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “project,” “estimate,” “expect,” “believe”, “future,” “likely,” “may,” “should,” “could”, “will” and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon’s plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled “Risk Factors” in Burcon’s annual information form dated June 27, 2016 filed with the Canadian securities administrators on www.sedar.com and contained in Burcon’s 20-F filed with the U.S. Securities and Exchange Commission on www.sec.gov. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


News Article | May 9, 2017
Site: globenewswire.com

VANCOUVER, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BUR) (“Burcon”) is pleased to announce today that it has been granted a U.S. patent, covering technology for the production of its Peazazz® pea protein:  U.S. patent no. 9,635,875, was granted on May 2, 2017.  This patent is the first to be granted for Burcon’s pea technology by the United States Patent and Trademark Office and confirms that the Company’s approach is unique, distinct and defensible.  Burcon anticipates further positive progress, with its patent filings, in due course.  Burcon also announces today that it has been granted two more U.S. patents covering technologies for the production of CLARISOY™, and it has also received two notices of allowance from the United States Patent and Trademark Office for two more patents for the production of CLARISOY™ soy protein.  A notice of allowance from the United States Patent and Trademark Office is a written notification that a patent application has cleared internal review, is pending issuance and will grant in the near future.  CLARISOY™ soy protein patents: U.S. patent no. 9,629,381 was granted April 25, 2017; and U.S. patent no. 9,603,377 was granted on March 28, 2017; and U.S. patent application 15/094386 was allowed on March 14, 2017, and U.S. patent application 14/117384 was allowed on March 29, 2017. The five U.S. patent grants and allowances, as announced above, bring the company’s patent portfolio to over 215 issued patents in various countries, including 65 in the U.S., as well as over 350 active patent applications, including 47 additional U.S. patent applications. Also, during the first part of 2017, Burcon continued its efforts toward commercializing its other unique plant protein extraction technologies. Burcon has focused in particular on working with a select group of potential partners in the commercialization process for our Peazazz® pea protein. The team at the Winnipeg Technical Centre continues to support these ongoing discussions with: due diligence visits; applications work; and sample production. The potential partners’ activities have included undertaking applications work, detailed market analyses and the investigation of production logistics. "The interest in, and need for, alternative plant protein ingredients continue to be a major trend within the food, beverage and nutritional products industries," said Johann Tergesen, Burcon’s president and chief operating officer, adding, “We are thrilled to see Burcon’s novel plant proteins progressing toward full commercialization and are confident of our ability to profit from this major trend.”  About Burcon NutraScience Corporation Burcon NutraScience is a leader in developing functionally and nutritionally valuable plant-based proteins. The company has developed a portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon’s CLARISOY™ soy protein offers clarity and high-quality protein nutrition for low pH beverage systems and excellent solubility and exceptionally clean flavor at any pH; Peazazz® is a uniquely soluble and clean-tasting pea protein; and Puratein®, Supertein® and Nutratein® are canola protein isolates with unique functional and nutritional attributes. For more information about the company, visit www.burcon.ca. The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “project,” “estimate,” “expect,” “believe”, “future,” “likely,” “may,” “should,” “could”, “will” and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon’s plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled “Risk Factors” in Burcon’s annual information form dated June 27, 2016 filed with the Canadian securities administrators on www.sedar.com and contained in Burcon’s 20-F filed with the U.S. Securities and Exchange Commission on www.sec.gov. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


News Article | May 9, 2017
Site: globenewswire.com

VANCOUVER, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BUR) (“Burcon”) is pleased to announce today that it has been granted a U.S. patent, covering technology for the production of its Peazazz® pea protein:  U.S. patent no. 9,635,875, was granted on May 2, 2017.  This patent is the first to be granted for Burcon’s pea technology by the United States Patent and Trademark Office and confirms that the Company’s approach is unique, distinct and defensible.  Burcon anticipates further positive progress, with its patent filings, in due course.  Burcon also announces today that it has been granted two more U.S. patents covering technologies for the production of CLARISOY™, and it has also received two notices of allowance from the United States Patent and Trademark Office for two more patents for the production of CLARISOY™ soy protein.  A notice of allowance from the United States Patent and Trademark Office is a written notification that a patent application has cleared internal review, is pending issuance and will grant in the near future.  CLARISOY™ soy protein patents: U.S. patent no. 9,629,381 was granted April 25, 2017; and U.S. patent no. 9,603,377 was granted on March 28, 2017; and U.S. patent application 15/094386 was allowed on March 14, 2017, and U.S. patent application 14/117384 was allowed on March 29, 2017. The five U.S. patent grants and allowances, as announced above, bring the company’s patent portfolio to over 215 issued patents in various countries, including 65 in the U.S., as well as over 350 active patent applications, including 47 additional U.S. patent applications. Also, during the first part of 2017, Burcon continued its efforts toward commercializing its other unique plant protein extraction technologies. Burcon has focused in particular on working with a select group of potential partners in the commercialization process for our Peazazz® pea protein. The team at the Winnipeg Technical Centre continues to support these ongoing discussions with: due diligence visits; applications work; and sample production. The potential partners’ activities have included undertaking applications work, detailed market analyses and the investigation of production logistics. "The interest in, and need for, alternative plant protein ingredients continue to be a major trend within the food, beverage and nutritional products industries," said Johann Tergesen, Burcon’s president and chief operating officer, adding, “We are thrilled to see Burcon’s novel plant proteins progressing toward full commercialization and are confident of our ability to profit from this major trend.”  About Burcon NutraScience Corporation Burcon NutraScience is a leader in developing functionally and nutritionally valuable plant-based proteins. The company has developed a portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon’s CLARISOY™ soy protein offers clarity and high-quality protein nutrition for low pH beverage systems and excellent solubility and exceptionally clean flavor at any pH; Peazazz® is a uniquely soluble and clean-tasting pea protein; and Puratein®, Supertein® and Nutratein® are canola protein isolates with unique functional and nutritional attributes. For more information about the company, visit www.burcon.ca. The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “project,” “estimate,” “expect,” “believe”, “future,” “likely,” “may,” “should,” “could”, “will” and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon’s plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled “Risk Factors” in Burcon’s annual information form dated June 27, 2016 filed with the Canadian securities administrators on www.sedar.com and contained in Burcon’s 20-F filed with the U.S. Securities and Exchange Commission on www.sec.gov. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


News Article | May 9, 2017
Site: globenewswire.com

VANCOUVER, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BUR) (“Burcon”) is pleased to announce today that it has been granted a U.S. patent, covering technology for the production of its Peazazz® pea protein:  U.S. patent no. 9,635,875, was granted on May 2, 2017.  This patent is the first to be granted for Burcon’s pea technology by the United States Patent and Trademark Office and confirms that the Company’s approach is unique, distinct and defensible.  Burcon anticipates further positive progress, with its patent filings, in due course.  Burcon also announces today that it has been granted two more U.S. patents covering technologies for the production of CLARISOY™, and it has also received two notices of allowance from the United States Patent and Trademark Office for two more patents for the production of CLARISOY™ soy protein.  A notice of allowance from the United States Patent and Trademark Office is a written notification that a patent application has cleared internal review, is pending issuance and will grant in the near future.  CLARISOY™ soy protein patents: U.S. patent no. 9,629,381 was granted April 25, 2017; and U.S. patent no. 9,603,377 was granted on March 28, 2017; and U.S. patent application 15/094386 was allowed on March 14, 2017, and U.S. patent application 14/117384 was allowed on March 29, 2017. The five U.S. patent grants and allowances, as announced above, bring the company’s patent portfolio to over 215 issued patents in various countries, including 65 in the U.S., as well as over 350 active patent applications, including 47 additional U.S. patent applications. Also, during the first part of 2017, Burcon continued its efforts toward commercializing its other unique plant protein extraction technologies. Burcon has focused in particular on working with a select group of potential partners in the commercialization process for our Peazazz® pea protein. The team at the Winnipeg Technical Centre continues to support these ongoing discussions with: due diligence visits; applications work; and sample production. The potential partners’ activities have included undertaking applications work, detailed market analyses and the investigation of production logistics. "The interest in, and need for, alternative plant protein ingredients continue to be a major trend within the food, beverage and nutritional products industries," said Johann Tergesen, Burcon’s president and chief operating officer, adding, “We are thrilled to see Burcon’s novel plant proteins progressing toward full commercialization and are confident of our ability to profit from this major trend.”  About Burcon NutraScience Corporation Burcon NutraScience is a leader in developing functionally and nutritionally valuable plant-based proteins. The company has developed a portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon’s CLARISOY™ soy protein offers clarity and high-quality protein nutrition for low pH beverage systems and excellent solubility and exceptionally clean flavor at any pH; Peazazz® is a uniquely soluble and clean-tasting pea protein; and Puratein®, Supertein® and Nutratein® are canola protein isolates with unique functional and nutritional attributes. For more information about the company, visit www.burcon.ca. The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “project,” “estimate,” “expect,” “believe”, “future,” “likely,” “may,” “should,” “could”, “will” and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon’s plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled “Risk Factors” in Burcon’s annual information form dated June 27, 2016 filed with the Canadian securities administrators on www.sedar.com and contained in Burcon’s 20-F filed with the U.S. Securities and Exchange Commission on www.sec.gov. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--Calyxt, Inc., a Minnesota-based company developing healthier food products to benefit both consumers and farmers, today announced that U.S. patent 8,921,332, which claims the use of chimeric restriction endonucleases for directing chromosomal gene editing in cells by homologous recombination (HR), initially issued on Dec. 30, 2014, has been upheld by the United States Patent and Trademark Office (USPTO) after a reexamination initiated in October 2015. U.S. patent 8,921,332 claims a general method for modifying chromosomal DNA sequences at a genomic site of interest within a cell by using chimeric restriction endonucleases, such as zing finger nucleases, TAL-effector nucleases, Mega-TALs and CRISPR/Cas9. This technique, commonly referred to as gene targeting or targeted insertion, is now frequently used to modify the genome within plants, animals and cell lines. The inventors of this patent are Dr. André Choulika, Cellectis CEO, and Dr. Richard Mulligan, a Harvard Medical School Professor. Institut Pasteur and Boston Children’s Hospital, the owners of the patent, have granted exclusive rights under this patent to Cellectis, Calyxt’s parent company. It belongs to a patent family that claims the basic uses of chimeric restriction nucleases for gene editing in cells. Following the patent’s reexamination, the USPTO issued a Notice to Issue Reexamination Certificate in which it is stated that all 55 claims of the patent are maintained, asserting that, "The '632 patent, Smith et al., the '150 patent, Kim et al. and the '261 patent individually or in combination neither teach or suggest the method of modifying a specific sequence in a chromosomal DNA of a cell in vitro by contacting the cell with a chimeric restriction endonuclease and a targeted DNA as recited in the present claims." Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. By combining its leading gene-editing technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier food ingredients for consumers and agriculturally advantageous traits for farmers. Calyxt is developing or creating specialty food ingredients, such as healthier oils and high fiber wheat, and food crops with desirable traits such as herbicide tolerance. Calyxt is located in Minneapolis-St. Paul, Minn., and is a wholly owned subsidiary of Cellectis. For further information please visit our website: www.calyxt.com Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc. Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

Loading United States Patent and Trademark collaborators
Loading United States Patent and Trademark collaborators